Drug maker begins operations in Hungary

A new drug company, Astellas Pharma Kft began operations in Hungary and expects a turnover of Ft 3.4 billion-Ft 4 billion in its first fiscal year, management said.

Manager György Markovich said the firm, a subsidiary of Astellas Europe Ltd, is starting operations with a staff of 40 and will be producing dermatological, urological and transplantation products. Their target for the next three or four years is to gain a 1% share of the Hungarian market, valued at about Ft 5 billion, Markovich said.

Initiatives

Budapest and UNICEF Hungary Partner to Involve Young People in Climate Planning

Economy

CEE4Impact Day Tests Case for Regenerative Capitalism in CEE

Banking

OTP Says Exposure Limited as Paraguay’s Ueno Bank Enters Insolvency

Residential

Buyers Push Back against Overpriced Homes as Market Shifts

SUPPORT THE BUDAPEST BUSINESS JOURNAL

Producing journalism that is worthy of the name is a costly business. For over 30 years, the publishers, editors and reporters of the Budapest Business Journal have striven to bring you business news that works, information that you can trust, that is factual, accurate and presented without fear or favor.Newspaper organizations across the globe have struggled to find a business model that allows them to continue to excel, without compromising their ability to perform. Most recently, some have experimented with the idea of involving their most important stakeholders, their readers.
We would like to offer that same opportunity to our readers. We would like to invite you to help us deliver the quality business journalism you require. Hit our Support the BBJ button and you can choose the how much and how often you send us your contributions.